BioNTech: Betting Big on Chinese Oncology Innovation
Once a little-known mRNA pioneer, BioNTech became a household name with its COVID-19 vaccine developed alongside Pfizer. But the German biotech is now pursuing an even bigger transformation — and…
Address: Neuhauser Str. 47, D-80331 München,Germany
Tel: +49-(0)89-23 66 50-0
Conreso is a German contract research organization which has set a benchmark with its unequaled quality. Both national and international customers benefit from the exceptional efficiency, pleasantly fast pace and incomparable willingness to provide service.Satisfied customers reward Conreso with their loyalty. The repeat business quote was consistently 90% over the past ten years. With their highly qualified employees, Conreso combines the professional scientific expertise of an academic institute with the efficiency of a CRO.CRO Muenchen was founded in 1990 by Jürgen Schäfer, with the aim of conducting studies in Germany according to FDA standards, which was not considered to be standard practice in Europe at that time. After over 17 years, CRO Muenchen changes its name to Conreso.
Once a little-known mRNA pioneer, BioNTech became a household name with its COVID-19 vaccine developed alongside Pfizer. But the German biotech is now pursuing an even bigger transformation — and…
A summary of some of the top stories coming out of Germany’s biopharma industry, including Bayer’s EMA win for its Eylea eye therapy; the oncology deal Merck KGaA has cut…
After February’s snap election that brought Friedrich Merz to power, a coalition between his conservative CDU/CSU bloc and the centre-left SPD has outlined an agreement this month that will serve…
Rainer Westermann, chairman of the Life Sciences Acceleration Alliance e.V. looks out over the choppy waters for life sciences venture capitalists in Europe over 2025. Three key initiatives stand to…
European pharma is at a turning point, with rising cost pressures, regulatory shifts, and supply chain vulnerabilities reshaping the industry. As the new president of Medicines for Europe, STADA’s Stephan…
A roundup of the biggest stories coming out of Germany’s pharma industry, including Bayer’s biggest share price drop in 20 years; Fresenius Kabi’s biosimilar deal with SamChunDang Pharm; Halozyme Therapeutics’…
The latest news from German pharma, including why Merck KGaA is looking to life science M&A; positive outlooks for Bayer and STADA; BioNTech’s move into the AI lab assistant space…
A roundup of some of the biggest stories coming out of German pharma, including Merck’s better-than-expected Q1 earnings; Stada’s possible return to the stock market; CDMO Vetter’s expanded capacity in…
Oskar Möbert, vice president of Veeva OpenData, discusses how standardizing customer reference data and systems organization-wide can help biopharmas scale globally and become more agile in their business. Data…
The biggest pharma industry and healthcare stories from Germany, including the country’s legalisation of cannabis; the MASH potential of Boehringer Ingelheim’s obesity candidate; Bayer’s further share price drop and expansion…
Pharma is rushing to adopt AI-driven tools in the hope of revolutionizing everything from drug discovery to clinical trials, regulatory submissions, and marketing efforts. While AI is the technology du…
Susanne Schaffert’s over 20-year stint at Novartis culminated with her presidency of the Swiss giant’s global oncology division, but when the company underwent a major restructure in 2022, she found…
See our Cookie Privacy Policy Here
